Brought to you by 
Incyte pays $45mm up front for rights to Calithera's arginase inhibitor
29 Oct 2021
Executive Summary
Incyte Corp. licensed global rights to develop and sell Calithera Biosciences Inc.’s arginase inhibitor CB1158 in hematology and oncology indications. Incyte paid $45mm up front and made an $8mm equity investment through the purchase of 1.7mm Calithera common shares at $4.65 (a slight premium).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Incyte pays $45mm up front for rights to Calithera's arginase inhibitor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice